WO2023097111A3 - Methods and compositions for treating calcinosis associated conditions - Google Patents
Methods and compositions for treating calcinosis associated conditions Download PDFInfo
- Publication number
- WO2023097111A3 WO2023097111A3 PCT/US2022/051222 US2022051222W WO2023097111A3 WO 2023097111 A3 WO2023097111 A3 WO 2023097111A3 US 2022051222 W US2022051222 W US 2022051222W WO 2023097111 A3 WO2023097111 A3 WO 2023097111A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- methods
- subject
- proteins
- treating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000004434 Calcinosis Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 210000002540 macrophage Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108010033040 Histones Proteins 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 102000034285 signal transducing proteins Human genes 0.000 abstract 1
- 108091006024 signal transducing proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/536,882 US20220143130A1 (en) | 2018-08-29 | 2021-11-29 | Peptides Having Immunomodulatory Properties |
| US17/536,882 | 2021-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023097111A2 WO2023097111A2 (en) | 2023-06-01 |
| WO2023097111A3 true WO2023097111A3 (en) | 2023-08-10 |
Family
ID=86540377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2022/051222 WO2023097111A2 (en) | 2021-11-29 | 2022-11-29 | Methods and compositions for treating calcinosis associated conditions |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023097111A2 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| US20160083482A1 (en) * | 2013-05-23 | 2016-03-24 | Shire Human Genetic Therapies Inc. | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
| US20160101150A1 (en) * | 2014-10-14 | 2016-04-14 | Riptide Bioscience, Inc. | Peptides having anti-inflammatory properties |
| US20190151304A1 (en) * | 2016-05-10 | 2019-05-23 | Inserm (Institut National De La Santé Et De La Rechercjae Médicale | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
| US20210340132A1 (en) * | 2012-08-09 | 2021-11-04 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US20220143130A1 (en) * | 2018-08-29 | 2022-05-12 | Riptide Bioscience, Inc. | Peptides Having Immunomodulatory Properties |
-
2022
- 2022-11-29 WO PCT/US2022/051222 patent/WO2023097111A2/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| US20210340132A1 (en) * | 2012-08-09 | 2021-11-04 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US20160083482A1 (en) * | 2013-05-23 | 2016-03-24 | Shire Human Genetic Therapies Inc. | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
| US20160101150A1 (en) * | 2014-10-14 | 2016-04-14 | Riptide Bioscience, Inc. | Peptides having anti-inflammatory properties |
| US20190151304A1 (en) * | 2016-05-10 | 2019-05-23 | Inserm (Institut National De La Santé Et De La Rechercjae Médicale | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
| US20220143130A1 (en) * | 2018-08-29 | 2022-05-12 | Riptide Bioscience, Inc. | Peptides Having Immunomodulatory Properties |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023097111A2 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2317620T3 (en) | FRAGMENTS OF HUMAN CORIONIC GONADOTROPINE (HCG) AS IMMUNOR REGULATOR. | |
| US9012404B2 (en) | Compositions and methods for cardiac tissue protection and regeneration | |
| US6262021B1 (en) | Use of substances having oxytocin activity for preparation of medicaments for wound healing | |
| US20120088733A1 (en) | Novel use of antimicrobial peptides in regeneration of skin cells | |
| NO326298B1 (en) | Use of R'-Glu-Trp-R '' dipeptides in the preparation of drugs | |
| RU2001116077A (en) | A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia | |
| CA2502146A1 (en) | Solution formulations of sirolimus and its analogs for cad treatment | |
| US20140024588A1 (en) | Method for inducing sustained immune response | |
| CN108135965B (en) | Pharmaceutical composition for wound healing containing substance P | |
| TWI587867B (en) | Short bio-active peptides for promoting wound healing | |
| RU2006110623A (en) | AGENT FROM THE SPLEEN OF THE LAND TURTLE STIMULATING HEMOPOESIS IN MAMMALS | |
| RU2569302C2 (en) | Compounds and pharmaceutic combinations for treatment of neurodegenerative and ischemic brain diseases | |
| CA2748392C (en) | Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) | |
| WO2023097111A3 (en) | Methods and compositions for treating calcinosis associated conditions | |
| US20170209498A1 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerve | |
| CN102363040A (en) | Antimicrobial peptide preparation for mucosal tissues | |
| AU2010217889B2 (en) | Peptidomimetic cyclic compounds for treating retinitis pigmentosa | |
| KR20200044434A (en) | Composition for treating intractable ulcer comprising substance P | |
| Caicedo et al. | Growth Hormone (GH) and Wound Healing | |
| WO2012046922A1 (en) | Novel use of antimicrobial peptides in regeneration of skin cells | |
| AU2002365974A1 (en) | Alpha-fetoprotein peptides and uses thereof | |
| WO2020018455A1 (en) | Compositions and methods for the treatment of traumatic optic neuropathy | |
| RU2694906C2 (en) | Ezrin derivatives peptides and pharmaceutical compositions based thereon | |
| RU2423971C1 (en) | Method of accelerating healing of skin injuries, caused by denervation and blood supply disturbance | |
| WO1999017758A3 (en) | Treatment of sickle cell anemia crises with fructose-1,6-diphosphate as an analgesic drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22899458 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |